About

Provided by Wachtell, Lipton, Rosen & Katz

A Preeminent Corporate Practice

Wachtell Lipton enjoys a global reputation as one of the world’s leading business law firms. Our deep experience means we regularly handle many of the largest, most complex and demanding transactions in the United States and around the world. We counsel both public and private acquirors and targets, advising on a wide range of corporate matters, including:

  • U.S., Cross-Border and International Mergers and Acquisitions
  • Private Equity and Strategic Investments
  • Spin-offs and Split-ups
  • Securities Offerings and Other Capital-Raising Transactions

In addition, we are recognized as a leading firm for:

  • Takeover Defense
  • Shareholder Activism
  • Corporate Governance

What We Have Done

Wachtell Lipton consistently ranks near the very top of legal advisors by transaction dollar volume, notwithstanding that we are significantly smaller than all of our major competitors. Over the past five years, we have been a legal advisor on eight of the ten largest transactions in the United States and seven of the ten largest transactions globally, as well as numerous other acquisition and restructuring transactions across many industries and of every description.

Representative major U.S. M&A matters can be found here.

Representative major cross-border or non-U.S. M&A matters can be found here.

Chambers Review

Provided by Chambers

Corporate/M&A: The Elite - USA - Nationwide

1
Band 1

What the Team is Known For

Wachtell, Lipton, Rosen & Katz is a highly esteemed practice that continues to be recognized as a formidable force in the M&A arena. The firm houses a talented bench of attorneys based in New York that regularly leads on high-end and complex transactions, both in the US and internationally. Its client base includes foremost public companies and financial institutions.

Notable practitioners

New York-based Adam Emmerich is a key contact.

Work Highlights

Provided by Wachtell, Lipton, Rosen & Katz

  • Wachtell, Lipton, Rosen & Katz represented Pfizer in its acquisition of Seagen for $43 billion.

Strengths

Provided by Chambers